RecallRadar

FDA Drug recall D-0015-2024

fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride / Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, R…

On 2023-10-11 the FDA classified a Class II recall of fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride / Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, R… by Central Admixture Pharmacy Services, citing lack of assurance of sterility:.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0015-2024
ClassificationClass II
Statusterminated
Initiated2023-09-21
Published2023-10-11
Last updated2026-09-13 11:52 UTC
CompanyCentral Admixture Pharmacy Services
DistributionUS

Product

fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride / Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2080-2

Reason

Lack of assurance of sterility:

Identifiers

code_infoLot: 17-275165, 17-275166, Exp. 10/1/2023; 17-275217, Exp. 10/2/2023; 17-275715, Exp. 10/9/2023; 17-276035, Exp. 10/16/2023; 17-276112, Exp. 10/17/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0015-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.